Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa... by John P. Savaryn, Richard L. Smith, Matthew Rosebraugh, Melina Neenan, Richard Burton, Kennan Marsh, David Wagner

Subjects: Get full text

A patient with Parkinson’s disease whose sleep status improved after the introduction of continuous subcutaneous foslevodopa/foscarbidopa infusion by Hirotaka Sakuramoto, Hiroaki Fujita, Keitaro Ogaki, Keisuke Suzuki

Subjects: “…Continuous subcutaneous foslevodopa/foscarbidopa infusion…”
Get full text

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study by Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung

Subjects: Get full text